QIBA Ultrasound Shear Wave Speed (SWS) Technical Committee

Friday, May 9, 2014; 11 AM CT Draft Call Summary

In attendance			RSNA
Brian Garra, MD (Co-Chair)	Steven E. Fick, PhD	Stephen McAleavey, PhD	Joe Koudelik
Tim J. Hall, PhD (Co-Chair)	Alpana Harisinghani, MD	Mark Palmeri, MD, PhD	Julie Lisiecki
Kaisar Alam, PhD	Christopher Hazard, PhD	Nicolas Rognin, MSc, PhD	
Michael Andre, PhD	James Jago, PhD	Matthew Urban, PhD	
Paul Carson, PhD	Jingfeng Jiang, PhD	Keith Wear, PhD	
Shigao Chen, PhD	Mike MacDonald, PhD	Hua Xie, PhD	
Manish Dhyani, MD			

Moderators: Dr. Hall

Discussion

- The call summary from the last meeting was approved
- The process and timeline for QIBA Round-4 funding proposal approval was reviewed
- Dr. Hall reviewed proposals for QIBA funding consideration
- Pls of Round-4 projects agreed to combine phantom/ simulation studies to maximize team efforts
- A status report is needed for the current year project (2013) for the University of Wisconsin
 - Project PIs were reminded that all current funded projects must be completed by the September 29,
 2014; regular progress reports will be important to aid in the accomplishment of this goal.
- Revised project concepts for Round-4are due to RSNA staff (<u>jkoudelik@rsna.org</u>) by close of business on Monday, May 12^{th.}
- Dr. Hall would like hold a follow-up discussion of the phantom study design parameters on the June 6th System Dependencies/ Phantom call.
 - A recent call summary of these parameters will be the starting point for this discussion.
 - o Items to be considered for the experiment design include:
 - Protocol
 - Bias
 - Sequence of timing
 - Participants
 - Phantom Study, Phase I may be referred to as a guide.
- Discussion of next biomarker effort/ follow up with AIUM:
 - Dr. Carson has prepared a survey, entitled, "QIBA survey of quantitative imaging biomarker Profile effort."
 - A collaboration with AIUM committees is being considered with mentoring provided by QIBA.
 - AIUM members will be able to rank their top choices for next biomarker consideration
 - Dr. Garra suggested that a summary be added for each biomarker under consideration to aid in the decision-making process.
 - Dr. Garra to review final version of survey prior to distribution.
 - o Additional considerations for a biomarker discussion may include the following:
 - Lack of 2-D imaging reproducibility
 - 3D imaging is key
 - Standardization of contrast imaging is also very important
 - Technology and how it may be useful in a clinical environment

Action Items:

- Dr. Carson to add a brief summary paragraph for each biomarker under consideration for the AIUM/ QIBA collaboration survey.
- Dr. Carson to send latest version of the AIUM survey to Dr. Garra for a final review prior to distribution.

Subcommittee Updates: Detailed project updates may be found on each subcommittee's page: QIBA wiki

Remaining call for May:

Date	Time (CT)	Day	Committee/ Subcommittee	Moderator
05/30/2014	11:00 am CT	Friday	US SWS Clinical Applications Subcommittee	Dr. Samir

Proposed Schedule for June:

Date	Time (CT)	Day	Committee/ Subcommittee	Moderator
06/06/2014	11:00 am CT	Friday	COMBINED: System Dependencies / Phantom Subcommittees Call	Dr. Wear
06/13/2014	11:00 am CT	Friday	US SWS Technical Committee	Mr. Milkowski
06/20/2014	11:00 am CT	Friday	COMBINED: System Dependencies / Phantom Subcommittees Call	Dr. Palmeri
06/27/2014	11:00 am CT	Friday	US SWS Clinical Applications Subcommittee	Dr. Samir

Conferences for Ultrasound on QIBA Wiki